Literature DB >> 17625968

B cell modulation in rheumatology.

Gregg J Silverman1, Sahil Khanna.   

Abstract

While evidence of dysregulation of the B cell compartment was first demonstrated with the identification of autoantibodies, other functional roles of B lymphocytes in autoimmune pathogenesis have generally been underappreciated or completely overlooked. With the recent approval of the first B cell targeting agent in rheumatoid arthritis, new strategies are being developed to target B cells through a range of membrane-associated lineage-specific molecules and also by interfering with B-cell-specific pro-survival signals. B-cell-directed agents therefore provide an effective new mechanistic approach to treatment and also enable new perspectives from the dissection of the contributions of B cells in physiologic and pathologic immune responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17625968      PMCID: PMC2693398          DOI: 10.1016/j.coph.2007.05.006

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  49 in total

Review 1.  B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

Authors:  T Shaw; J Quan; M C Totoritis
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 2.  Lymphotoxin/light, lymphoid microenvironments and autoimmune disease.

Authors:  Jennifer L Gommerman; Jeffrey L Browning
Journal:  Nat Rev Immunol       Date:  2003-08       Impact factor: 53.106

3.  Effect of the B cell superantigen protein A from S. aureus on the early lupus disease of (NZBxNZW) F1 mice.

Authors:  Muriel Viau; Moncef Zouali
Journal:  Mol Immunol       Date:  2004-11-23       Impact factor: 4.407

4.  Mouse CD20 expression and function.

Authors:  Junji Uchida; Youngkyun Lee; Minoru Hasegawa; Yinghua Liang; Alice Bradney; Julie A Oliver; Kristina Bowen; Douglas A Steeber; Karen M Haas; Jonathan C Poe; Thomas F Tedder
Journal:  Int Immunol       Date:  2004-01       Impact factor: 4.823

5.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

6.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

Review 7.  Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?

Authors:  J Schiffenbauer; L S Simon
Journal:  Lupus       Date:  2004       Impact factor: 2.911

Review 8.  From the bench to the bedside: ways to improve rituximab efficacy.

Authors:  Guillaume Cartron; Hervé Watier; Josée Golay; Philippe Solal-Celigny
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

9.  Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response.

Authors:  R K Do; E Hatada; H Lee; M R Tourigny; D Hilbert; S Chen-Kiang
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.

Authors:  Junji Uchida; Yasuhito Hamaguchi; Julie A Oliver; Jeffrey V Ravetch; Jonathan C Poe; Karen M Haas; Thomas F Tedder
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307

View more
  2 in total

1.  Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice.

Authors:  Anshu Marathe; Suhasini Iyer; Zhihua Julia Qiu; Jennifer Visich; Donald E Mager
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

2.  Stress-related suppression of peripheral cytokines predicts future relapse in alcohol-dependent individuals with and without subclinical depression.

Authors:  Helen C Fox; Verica Milivojevic; Alicia MacDougall; Heather LaVallee; Christine Simpson; Gustavo A Angarita; Rajita Sinha
Journal:  Addict Biol       Date:  2019-11-17       Impact factor: 4.280

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.